San Francisco-based online healthcare platform Hims & Hers is disrupting a new healthcare category: The company just rolled out a bargain semaglutide medication that could compete with Ozempic. The Hims and Hers Weight Loss prescription kit starts at $79 per month for oral medications and $199 per month for injection-based kits, which could include GLP-1 medicine such as Ozempic, Wegovy, or similar off-brand medication. GLP-1 is a class of weight-loss drugs prescribed by licensed doctors that could suppress appetite and regulate blood sugar.
Business owners have contended with the rising popularity of these medications as they relate to their health care plans for employees . Some have been hesitant to add such a benefit to their coverage for many reasons-- one of which is the cost . Ozempic, for example, starts at $935 without insurance.
Not only is Hims coming in with a cheaper option for consumers--its semaglutide medication also doesn't require insurance. Customers seeking treatment can start by filling out a questionnaire covering their health history and goals on Hims' website. From there, a Hims' licensed provider will review their answers and BMI to determine if they qualify for treatment.
Those who do will receive a message with plan options--all of which is done entirely online, forgoing the traditional process of video visits or in-person appointments. This isn't the first time Hims & Hers founder Andrew Dudum has disrupted monopolized industries. He started the bu.